CN102659928B - Synthetic signal peptide and application thereof - Google Patents
Synthetic signal peptide and application thereof Download PDFInfo
- Publication number
- CN102659928B CN102659928B CN201210118675.7A CN201210118675A CN102659928B CN 102659928 B CN102659928 B CN 102659928B CN 201210118675 A CN201210118675 A CN 201210118675A CN 102659928 B CN102659928 B CN 102659928B
- Authority
- CN
- China
- Prior art keywords
- signal peptide
- polynucleotide
- expression vector
- protein
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010076504 Protein Sorting Signals Proteins 0.000 title claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 239000013604 expression vector Substances 0.000 claims abstract description 26
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 3
- 235000018102 proteins Nutrition 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 24
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 15
- 238000001890 transfection Methods 0.000 claims description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 7
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 7
- 230000003248 secreting effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000044890 human EPO Human genes 0.000 claims 5
- 230000014509 gene expression Effects 0.000 abstract description 26
- 230000028327 secretion Effects 0.000 abstract description 5
- 239000013612 plasmid Substances 0.000 description 21
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 17
- 102000003951 Erythropoietin Human genes 0.000 description 13
- 108090000394 Erythropoietin Proteins 0.000 description 13
- 229940105423 erythropoietin Drugs 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 7
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 4
- 102100031939 Erythropoietin Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 3
- 102000040739 Secretory proteins Human genes 0.000 description 3
- 108091058545 Secretory proteins Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to synthetic signal peptide and application thereof. The amino acid sequence of the signal peptide is SEQ ID NO:2. The signal peptide can be added to a mammalian cell expression vector and used for leading mammalian source protein secretion expression, and the foreign protein expression index of the signal peptide in mammalian cells can be improved.
Description
This case is dividing an application of following patent application:
Application number: 201010284904.3;
The applying date: on September 17th, 2010;
Denomination of invention: a kind of signal peptide of synthetic and application thereof
Technical field
The present invention relates to biological technical field, be specifically related to for guiding Mammals source protein in signal peptide and the application thereof of mammalian cell secreting, expressing.
Technical background
The high efficient expression of foreign gene in host cell is the prerequisite of structure and function analysis, protein or the polypeptide drug research and development of protein.For expressing the expression system of recombinant protein, there are microorganism, plant, yeast, insect cell and zooblast etc.Mammalian cell is to express the best host with natural radioactivity albumen, it is advantageous that synthetic, processing and the secretion signal that can correctly effectively identify eukaryotic protein, intron in identification and removal gene, through shearing, become ripe mRNA again, can complete exactly glycosylation, phosphorylation, form in chain and translate post-treatment process with interchain disulfide bond and proteolysis etc., thereby the complete antibody producing is the same with natural antibody, there is biologic activity, not only can identify antigen but also can activating complement system.Easily reorganized DNA transfection of mammalian cell, can obtain the cell that transforms through screening, have genetic stability and repeatability, and the product of expression is secreted into and in substratum, is easy to purifying.Utilize mammalian cell expression protein product to be widely used in biological products industry, as a large amount of preparations of virus vaccines, antibody, Interferon, rabbit, immunomodulator, hormone and somatomedin etc.But zooblast exogenous protein expression efficiency is low, and cost is high, therefore improves zooblast exogenous protein expression efficiency, and reducing production costs is the most important thing in work at present.
Affect the factor of exogenous protein in mammalian cell a lot, as signal peptide, transcribe and translate integration site on karyomit(e) of controlling elements, RNA processing (RNA Processing), the number of gene copy, the stability of mRNA, foreign gene, recombinant protein to the genome Preference of the genotoxic potential of host cell and host cell (genetic properties) etc.In the situation that expression vector is definite, it is most important that the selection of signal peptide just seems.
The N-end of secretory protein is comprised of the leader sequence of the 15-30Aa that can be sheared conventionally, this is sequentially called signal peptide (signal sequence), at N-end or near N end place, there is 2-3 polarity Aa, and at the middle part of signal peptide, be all a unique hydrophobic core or formed by a lot of hydrophobic Aa.In signal peptide, do not have other conservative order there is no acidic-group yet.With to lead peptide similar, signal peptide is to be also enough to any additional polypeptide to be transported into target film.The N-end that for example signal peptide is added in to globin, just can make it no longer stay in cytosol, but passes film and be secreted into outside born of the same parents.
Signal peptide can make the rrna of translating be attached on RER film.Rrna is to adhere to and synthesis secretion albumen by the function of signal peptide.So and indifference between free rrna and film binding ribosomal body own.Signal peptide is as the signal identification on a kind of ER of being attached to film, this may be by the N-termination that starts to synthesize several amino acid whose hydrophobic functions.Then protein chain injects in film, and signal peptide is embedded in a kind of proteolytic enzyme in film and shears at this moment rrna and completed translation, and albumen has prolonged leads peptide by way of passing film.The effect of signal peptide secretion foreign protein is as follows:
1) signal peptide can guide secretory protein or membranin to go out born of the same parents.
2) hydrophobic core of signal peptide determines the secernment efficiency of protein.
3) signal peptide can pilot protein matter in cell different zones or different organoid carry out correct location.
4) signal peptide can be secreted the secretion that enhanser strengthens foreign protein.
5) the glad molecule that is conducive to reduce expression vector of short signal is put, and improves and is incorporated into the stability of external source expression casette on host chromosome and transcribes efficiency.
For secretory protein, select suitable signal peptide its expression amount can be significantly improved, no matter for industrial production or scientific research, its meaning is all very far-reaching.
Summary of the invention
The object of the invention is to provide a kind of signal peptide and application thereof that can guide the high efficient expression of external source mammalian cell albumen, carrys out the production cost of source protein to reduce Mammals.
First, the invention provides a kind of synthetic for guiding Mammals source protein at the signal peptide of mammalian cell secreting, expressing, the aminoacid sequence of described signal peptide is arbitrary in SEQ ID NO:1-5.Wherein, the signal peptide of SEQ ID NO:1-5 has higher homology.
SEQ?ID?NO:1MDVLAFLLGLLLLWLPGVRC
SEQ?ID?NO:2MDVPAEFLGLLLLWLSGVRC
SEQ?ID?NO:3MRVLPEFLGLLLLWISGVRC
SEQ?ID?NO:4MDVPLQLLGLLLLWLSGVRC
SEQ?ID?NO:5MDVPAELLGLLLLWISGVRC
Described mammalian cell can be CHO, BHK, SP2/0, C127 etc.
Signal peptide of the present invention is used in mammalian host cell and guides Mammals to carry out the secreting, expressing of source protein.
The present invention also provides a kind of polynucleotide, described in described polynucleotide encoding for guiding Mammals source protein at the signal peptide of mammalian cell secreting, expressing.
Further, the sequence of described many nucleic acids is selected from arbitrary in SEQ ID NO:6-10:
ATGGATGTTCTTGCTTTTCTTCTGGGCTTGCTGCTTTTGTGGCTTCCCGGGGTGAGGTGC(SEQ?ID?NO:6)
ATGGATGTTCCTGCCGAATTTCTTGGATTGTTGTTGTTGTGGCTCTCCGGAGTGCGTTGC(SEQ?ID?NO:7)
ATGAGGGTTCTGCCTGAATTCCTGGGACTTTTGTTGTTGTGGATTTCCGGCGTGCGATGT(SEQ?ID?NO:8)
ATGGATGTACCACTTCAGCTTCTTGGCTTGTTGTTGCTTTGGCTTTCTGGCGTGAGATGT(SEQ?ID?NO:9)
ATGGATGTGCCTGCTGAACTTTTGGGCCTTCTTTTGTTGTGGATATCAGGAGTACGATGC(SEQ?ID?NO:10)
Polynucleotide of the present invention can be prepared by conventional synthetic method.
Polynucleotide of the present invention can make an addition to mammalian cell expression vector, for guiding Mammals to carry out the secreting, expressing of source protein.
Utilize signal peptide of the present invention secreting, expressing Mammals in zooblast to come the method for source protein to be: the polynucleotide of code book invention signal peptide and coding to be expressed to mammalian cell and come the polynucleotide of source protein to be connected rear clone to enter mammalian cell expression vector, then will after this recombinant mammalian cells expression vector transfection mammalian cell, express target protein.
The present invention also provides a kind of mammalian cell expression vector, the polynucleotide of the protein in the polynucleotide that described expression vector contains aforementioned code book invention signal peptide and encoding mammalian source.
In described expression vector, the polynucleotide front end of the protein that the polynucleotide of code book invention signal peptide are immediately originated at described encoding mammalian.
Further, in described expression vector, the front end of the polynucleotide of described code book invention signal peptide is added with Kozak sequence.
The promotor of described expression vector can be EF-1 α promotor, CMV promotor, SV40 late promoter or SV40 early promoter etc.
As the embodiment of the present invention is enumerated, described expression vector is the pIRESneo3 of transformation, in the pIRESneo3 of described transformation, people EF-1 α promoter sequence or people EF1-HTLV promoter sequence have been replaced the main immediate early promoter sequence of hCMV in pIRESneo3 plasmid.
The present invention also provides a kind of mammalian host cell, and described host cell is the transfection of aforementioned expression vector institute.Described mammalian cell can be selected from CHO, BHK, SP2/0, C127 etc.
The present invention also further provides the method for producing protein in a kind of Mammals source, for under the condition of protein that is applicable to the described Mammals of expression source, cultivate aforementioned mammal host cell, then from culture, adopt ordinary method to isolate the protein in described Mammals source.
The protein in described Mammals source can be the protein of molecular weight arbitrarily, as various pharmaceutical proteins: erythropoietin, various there is erythropoietin activity change structure erythropoietin, and antibody etc.
The present invention compares signal peptide of the present invention and protein self signal peptide, the measurement result of exogenous protein expression amount shows, signal peptide of the present invention is specially adapted to Chinese hamster ovary celI, compare with existing signal peptide, exogenous protein expression amount in zooblast obtains significantly and promotes, expression level has improved approximately 2~36 times, and its application is conducive to screen the strain of high expression level monoclonal cell, has reducing production costs, is convenient to the advantages such as subsequent purification.
Accompanying drawing explanation
Fig. 1 shows the comparison (pEF carrier) of invention signal peptide and EPO self signal peptide
Fig. 2 shows the comparison (pEV carrier) of invention signal peptide and EPO self signal peptide
Embodiment
Following embodiment describes the present invention in detail, but its invention scope is not limited
The expression vector that the embodiment of the present invention is cited is to be obtained by Plasmid pIRES neo3 transformation.Wherein, people EF-1 α promoter sequence, people EF1-HTLV promoter sequence have been replaced respectively the main immediate early promoter of hCMV (the Human cytomegalovirus major immediate early promoter) sequence in former plasmid.
Synthesizing of embodiment 1 signal peptide
Shorter because of signal peptide, signal peptide is pressed to primer synthetic.5 ' end adds NheI restriction enzyme site and Kozak sequence, and 3 ' end adding purpose gene order part, so that add this signal peptide on goal gene.
Signalase 11:
tCGGAGCTAGCCACCaTGGATGTTCTTGCTTTTCTTCTGGGCTTGCTGCTTTTGTGGCTTCCCGGGGTGAG GTGC
gCCCCACCACG(SEQ ID NO:11)
Signal peptide 2:
tCGGAGCTAGCCACCaTGGATGTTCCTGCCGAATTTCTTGGATTGTTGTTGTTGTGGCTCTCCGGAGTGCG TTGC
gCCCCACCACG(SEQ ID NO:12)
Signal peptide 3:
tCGGAGCTAGCCaCCATGAGGGTTCTGCCTGAATTCCTGGGACTTTTGTTGTTGTGGATTTCCGGCGT GCGATGT
gCCCCACCACG(SEQ ID NO:13)
Signal peptide 4:
tCGGAGCTAGCCACCaTGGATGTACCACTTCAGCTTCTTGGCTTGTTGTTGCTTTGGCTTTCTGGCGTGAG ATGT
gCCCCACCACG(SEQ ID NO:14)
Signal peptide 5:
tCGGAGCTAGCCACCaTGGATGTGCCTGCTGAACTTTTGGGCCTTCTTTTGTTGTGGATATCAGGAGTACG ATGC
gCCCCACCACG(SEQ ID NO:15)
The amplification of embodiment 2 people EF-1 α promotors
The plasmid pEF6/V5-HisA (purchased from Invitrogen company) of take is masterplate, and people EF-1 α promoter sequence is reference, and design primers F 01/R01, carries out polymerase chain reaction, amplifies people EF-1 α promoter sequence, and reaction conditions is as table 1.
F01:CATACTAGTGCTCCGGTGCCCGTCAGTGGGCAGAG(SEQ?ID?NO:16)
R01:ACGGCTAGCTCCGAGCTCGGTACCAAGCTTACCTAGCCA(SEQ?ID?NO:17)
Table 1PCR reaction conditions
Gained PCR product is connected with the pUC57 (purchased from Fermentas company) processing through SmaI, and the evaluation of checking order, and result shows that sequence is as follows:
ACTAGTGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTAGCTTGGTACTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGGTAAGCTTGGTACCGAGCTCGGAGCTAGC(SEQ?ID?NO:18)
The amplification of embodiment 3 people EF1-HTLV promotors
The plasmid pFUSE-CHIg-hG3 (purchased from InvivoGen company) of take is masterplate, and people EF1-HTLV promoter sequence is reference, and design primers F 02/R02, carries out polymerase chain reaction, amplifies people EF1-HTLV promoter sequence, and reaction conditions is as table 1.
F02:ACGACTAGTGCTCCGGTGCCCGTCAGTGGGCAGAGC(SEQ?ID?NO:19)
R02:ATCGCTAGCGTAGGCGCCGGTCACAGCT(SEQ?ID?NO:20)
Gained PCR product is connected with the pUC57 (purchased from Fermentas company) processing through SmaI, and the evaluation of checking order, and result shows that sequence is as follows:
ACTAGTGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACGCTAGC(SEQ?ID?NO:21)
The structure of embodiment 4 restructuring pEF expression vectors
Product in embodiment 2 and pIRESneo3 plasmid are carried out to SpeI/NheI double digestion and be connected, obtain plasmid pEF.
Human erythropoietin gene (the GeneBank accession number: AB463610 that codon is optimized, containing self signal peptide and 5 ' end, added Kozak sequence) respectively after the processing of NheI/BamHI double digestion, be connected to the plasmid pEF after NheI/BamHI double digestion, the recombinant plasmid called after pEF-EPO obtaining.
By signalase 11, signal peptide 2, signal peptide 3, signal peptide 4, signal peptide 5 carries out PCR splicing with erythropoietin (no signal peptide) respectively, and splicing product carries out respectively SpeI/NheI double digestion with plasmid pEF and is connected.The recombinant plasmid obtaining is called after pEF-EP01 respectively, pEF-EP02, pEF-EP03, pEF-EP04, pEF-EP05.
Embodiment 5 restructuring pEF expression vector transient transfection expression studies
Adopt liposome method (lipofectamine LTX, invitrogen) by plasmid pEF-EPO, pEF-EP01, pEF-EP02, pEF-EP03, pEF-EP04, pEF-EP05 is transfection CHO-S cell respectively, detects the transient expression level of its erythropoietin.
According to lipofectamine LTX process specifications, by 3 μ gpEF-EPO, pEF-EP01, pEF-EP02, pEF-EP03, pEF-EP04, pEF-EP05 plasmid respectively transfection is incubated at the CHO-S cell (approximately 1.1 * 10 of 6 orifice plates (2.5ml/well, 10% foetal calf serum)
6individual cell).Transfectional cell, at 5%CO2, is cultivated in the CO2gas incubator of 37 ℃ after 24 hours, collects nutrient solution supernatant, and expression product has erythropoietin activity through identifying, utilizes ELISA method to measure its erythropoietin expression amount.PEF-EPO, pEF-EP01, pEF-EP02, pEF-EP03, pEF-EP04, the expression amount of pEF-EP05 is respectively 3ng/ml, 73ng/ml, 100ng/ml, 62ng/ml, 85ng/ml, 110ng/ml.Result demonstration, signal peptide of the present invention is with respect to erythropoietin self signal peptide, and under the same conditions, EPO expression amount has improved 20~36 times.
The structure of embodiment 6 restructuring pEV expression vectors
Product in embodiment 3 and pIRESneo3 plasmid are carried out to SpeI/NheI double digestion and be connected, obtain plasmid pEF1-HTLV.
Human erythropoietin gene (the GeneBank accession number: AB463610 that codon is optimized, containing self signal peptide and 5 ' end, added Kozak sequence) respectively after the processing of NheI/BamHI double digestion, be connected to the plasmid pEV after NheI/BamHI double digestion, the recombinant plasmid called after pEV-EPO obtaining.
By signalase 11, signal peptide 2, signal peptide 3, signal peptide 4, signal peptide 5 carries out PCR splicing with erythropoietin (no signal peptide) respectively, and splicing product carries out respectively SpeI/NheI double digestion with plasmid pEV and is connected.The recombinant plasmid obtaining is called after pEV-EP01 respectively, pEV-EP02, pEV-EP03, pEV-EP04, pEV-EP05.
Embodiment 7 restructuring pEV expression vector transient transfection expression studies
Adopt liposome method (lipofectamine LTX, invitrogen) by plasmid pEV-EPO, pEV-EP01, pEV-EP02, pEV-EP03, pEV-EP04, pEV-EP05 is transfection CHO-S cell respectively, detects the transient expression level of its erythropoietin.
According to lipofectamine LTX process specifications, by 3 μ gpEV-EPO, pEV-EP01, pEV-EP02, pEV-EP03, pEV-EP04, pEV-EP05 plasmid respectively transfection is incubated at the CHO-S cell (approximately 1.1 * 10 of 6 orifice plates (2.5ml/well, 10% foetal calf serum)
6individual cell).Transfectional cell is at 5%CO
2, in the CO2gas incubator of 37 ℃, cultivate after 24 hours, collect nutrient solution supernatant, expression product has erythropoietin activity through identifying, utilizes ELISA method to measure its erythropoietin expression amount.PEV-EPO, pEV-EP01, pEV-EP02, pEV-EP03, pEV-EP04, the expression amount of pEV-EP05 is respectively 20ng/ml, 53ng/ml, 58ng/ml, 48ng/ml, 40ng/ml, 60ng/ml.Result demonstration, signal peptide of the present invention, with respect to erythropoietin self signal peptide, under the same conditions, has improved 2~3 times by EPO expression amount.
Claims (10)
- Synthetic for guiding Mammals source protein at a signal peptide for mammalian cell secreting, expressing, the aminoacid sequence of described signal peptide is as shown in SEQ ID NO:2, the protein in described Mammals source is human erythropoietin.
- 2. polynucleotide, signal peptide described in described polynucleotide encoding claim 1.
- 3. polynucleotide as claimed in claim 2, is characterized in that, the sequence of described polynucleotide is as shown in SEQ ID NO:7.
- 4. a mammalian cell expression vector, the polynucleotide that described expression vector contains polynucleotide and encoding human erythropoietin described in claim 2 or 3.
- 5. mammalian cell expression vector as claimed in claim 4, is characterized in that, polynucleotide are immediately at the polynucleotide front end of described encoding human erythropoietin described in claim 2 or 3.
- 6. mammalian cell expression vector as claimed in claim 4, is characterized in that, further, in described expression vector, the front end of polynucleotide is added with Kozak sequence described in claim 2 or 3.
- 7. mammalian cell expression vector as claimed in claim 4, is characterized in that, the promotor of described expression vector is selected from EF-1 α promotor, CMV promotor, SV40 late promoter or SV40 early promoter.
- 8. a mammalian host cell, described host cell is the transfection of the arbitrary described expression vector of claim 4-7 institute.
- 9. mammalian host cell as claimed in claim 8, is characterized in that, described mammalian host cell is CHO, BHK, SP2/0 or C127.
- 10. the method for producing protein in Mammals source, for being applicable to expressing under the condition of human erythropoietin, cultivates mammalian host cell described in claim 8 or 9, then from culture, isolates described human erythropoietin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210118675.7A CN102659928B (en) | 2010-09-17 | 2010-09-17 | Synthetic signal peptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210118675.7A CN102659928B (en) | 2010-09-17 | 2010-09-17 | Synthetic signal peptide and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010284904 Division CN101921315B (en) | 2010-09-17 | 2010-09-17 | Artificially synthesized signal peptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102659928A CN102659928A (en) | 2012-09-12 |
CN102659928B true CN102659928B (en) | 2014-02-05 |
Family
ID=46769534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210118675.7A Active CN102659928B (en) | 2010-09-17 | 2010-09-17 | Synthetic signal peptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102659928B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211776B (en) * | 2013-05-03 | 2017-11-28 | 南京工业大学 | Strong secretory signal peptide enhancing small peptide block and its application |
CN103254277B (en) * | 2013-05-03 | 2017-02-08 | 南京工业大学 | Small peptide strengthening mold sequence of strong secretory signal peptide and application thereof |
CN104974226B (en) * | 2014-04-01 | 2019-10-15 | 三生国健药业(上海)股份有限公司 | A kind of signal peptide for protein expression |
CN106478774B (en) * | 2015-08-25 | 2021-09-14 | 三生国健药业(上海)股份有限公司 | Signal peptide for protein expression |
CN106478773B (en) * | 2015-08-25 | 2021-09-14 | 三生国健药业(上海)股份有限公司 | Novel artificially synthesized signal peptide |
CN116769746B (en) * | 2023-05-12 | 2024-06-18 | 康彤(上海)生物研发有限公司 | Method for improving ability of pichia pastoris to secrete cyclodextrin glucosyltransferase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265143A (en) * | 1997-07-23 | 2000-08-30 | 罗切诊断学有限公司 | Prodn. of erythropoietin by endogenous gene activation |
CN101583716A (en) * | 2006-11-17 | 2009-11-18 | 加利福尼亚大学校务委员会 | Expression system of NELL peptide |
CN101687910A (en) * | 2007-06-04 | 2010-03-31 | 英国龙沙生物医药股份有限公司 | Mammalian expression vector with a highly efficient secretory signal sequence |
-
2010
- 2010-09-17 CN CN201210118675.7A patent/CN102659928B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265143A (en) * | 1997-07-23 | 2000-08-30 | 罗切诊断学有限公司 | Prodn. of erythropoietin by endogenous gene activation |
CN101583716A (en) * | 2006-11-17 | 2009-11-18 | 加利福尼亚大学校务委员会 | Expression system of NELL peptide |
CN101687910A (en) * | 2007-06-04 | 2010-03-31 | 英国龙沙生物医药股份有限公司 | Mammalian expression vector with a highly efficient secretory signal sequence |
Non-Patent Citations (5)
Title |
---|
MMP-9信号肽高效诱导PEX重组蛋白在COS7细胞中分泌表达;宋琳 等;《中国生物工程杂志》;20070515;第27卷(第5期);1-5 * |
宋琳 等.MMP-9信号肽高效诱导PEX重组蛋白在COS7细胞中分泌表达.《中国生物工程杂志》.2007,第27卷(第5期), |
张志谦 等.生长激素信号肽可诱导重组蛋白外分泌表达.《中国生物化学与分子生物学报》.2005,第21卷(第2期), |
生长激素信号肽可诱导重组蛋白外分泌表达;张志谦 等;《中国生物化学与分子生物学报》;20050415;第21卷(第2期);282-283 * |
黄利文 等.中国人促红细胞生成素基因组的克隆及其在COS-7细胞中的表达.《中国科学(B辑)》.1999,第24卷(第2期), * |
Also Published As
Publication number | Publication date |
---|---|
CN102659928A (en) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102659928B (en) | Synthetic signal peptide and application thereof | |
CN102165060B (en) | Novel regulatory elements | |
Boscolo et al. | Simple scale-up of recombinant antibody production using an UCOE containing vector | |
Mueller et al. | Noncleavable transmembrane mouse tumor necrosis factor-α (TNFα) mediates effects distinct from those of wild-type TNFα in vitro and in vivo | |
CN103201382A (en) | Novel expression vector | |
KR20090053893A (en) | Matrix attachment regions(mars) for increasing transcription and uses thereof | |
CN103483423B (en) | Artificially synthesized signal peptide and application thereof | |
CN101921315B (en) | Artificially synthesized signal peptide and application thereof | |
CN102659927B (en) | Synthetic signal peptide and application thereof | |
CN106478773B (en) | Novel artificially synthesized signal peptide | |
Thean et al. | To plate or to simply unfreeze, that is the question for optimal plasmid extraction | |
CN104974226A (en) | Signal peptide for protein expression | |
CN104059128A (en) | Artificially synthesized signal sequence and application thereof | |
CN102392047A (en) | Bicistronic mRNA (messenger ribonucleic acid) expression vector suitable for cells of mammals and application thereof | |
CN101906438B (en) | Method for expressing and producing recombinant human blood coagulation factors VII in animal cells | |
CN104975018B (en) | A kind of novel enhanced is sub and its applies | |
Campbell et al. | Identification of a gp63 surface glycoprotein in Leishmania tarentolae | |
CN110054667B (en) | Optimized pichia pastoris GS115 mating exohormone alpha-factor signal peptide and application thereof | |
CN106636123B (en) | Method for constructing rhIL-12 expression system in CHO cell | |
Liang et al. | Heterologous expression of human C‐reactive protein in the green alga Chlamydomonas reinhardtii | |
EP2933331A1 (en) | Expression cassette | |
CN106478774B (en) | Signal peptide for protein expression | |
CN114561430B (en) | expression vector for instantaneous expression of humanized cells, expression system, construction method and application thereof | |
CN117567607B (en) | Anti-CREG monoclonal antibody 20F6 and preparation method and application thereof | |
CN110028562B (en) | Optimized Komagataella pastoris yeast alpha-factor signal peptide and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |